title: How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
authors.forename: M A
authors.initials: MA
authors.lastname: Eisenberger
authors.forename: W G
authors.initials: WG
authors.lastname: Nelson
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D013498:Suramin / Q000494:pharmacology* / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D013498:Suramin; D017430:Prostate-Specific Antigen